Its business plan and technology under fire, Theranos appears to be playing metaphorical three-card monte with federal lawmakers and the laboratory community curious as to whether it will become a more transparent enterprise. Members of the U.S. House of Representatives’ Committee on Energy and Commerce have been pressing the California-based laboratory to produce a variety…

This content is for Paid Members only.
Login Register